3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
259
Lymphoid
13
Tumor-Agnostic
5
Gynecologic
3
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Genitourinary
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
6
lanreotide
5
Octreotide
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Capecitabine
3
surufatinib
2
pasireotide
2
fluorodopa F 18
2
Temozolomide
2
Lutetium-177
2
Lutetium
2
Introns
2
Ga(III)-DOTATOC
2
telotristat ethyl
1
pembrolizumab
1
copper dotatate CU-64
1
cabozantinib
1
X-Rays
1
Watchful Waiting
1
Sunitinib
1
Specimen Handling
1
Somatostatin
1
Serotonin
1
Salts
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Phantoms, Imaging
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Oxaliplatin
×
NET
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled